Research programme: antibody therapies - Hanwha Chemical
Alternative Names: HD 101; HD 104; HD 105; HD 106Latest Information Update: 28 Jul 2019
Price :
$50 *
At a glance
- Originator Hanwha Chemical
- Class Antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Multiple sclerosis; Rheumatoid arthritis
Most Recent Events
- 28 Jul 2019 No recent reports of development identified for research development in Rheumatoid-arthritis in South Korea
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in South Korea (Parenteral)
- 16 Jul 2016 No recent reports of development identified for research development in Multiple-sclerosis in South Korea